SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Taku Hatano, Nobutaka Hattori, Tadaaki Kawanabe, Yasuo Terayama, Norihiro Suzuki, Yasuo Iwasaki, Toshiki Fujioka, An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson’s disease, Journal of Neural Transmission, 2014, 121, 3, 275

    CrossRef

  2. 2
    P. Martinez-Martin, K. R. Chaudhuri, J. M. Rojo-Abuin, C. Rodriguez-Blazquez, M. Alvarez-Sanchez, T. Arakaki, A. Bergareche-Yarza, A. Chade, N. Garretto, O. Gershanik, M. M. Kurtis, J. C. Martinez-Castrillo, A. Mendoza-Rodriguez, H. P. Moore, M. Rodriguez-Violante, C. Singer, B. C. Tilley, J. Huang, G. T. Stebbins, C. G. Goetz, Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale, European Journal of Neurology, 2014, 21, 8
  3. 3
    Consider pharmacotherapy for neurogenic orthostatic hypotension only if non-pharmacological measures fail, Drugs & Therapy Perspectives, 2014, 30, 4, 135

    CrossRef

  4. 4
    C. Vriend, P. Raijmakers, D. J. Veltman, K. D. van Dijk, Y. D. van der Werf, E. M. J. Foncke, J. H. Smit, H. W. Berendse, O. A. van den Heuvel, Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus, Journal of Neurology, Neurosurgery & Psychiatry, 2014, 85, 2, 159

    CrossRef

  5. 5
    Melissa J. Armstrong, Diagnosis and Treatment of Corticobasal Degeneration, Current Treatment Options in Neurology, 2014, 16, 3

    CrossRef

  6. 6
    I. D. Grachev, Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships?, Journal of Neurology, Neurosurgery & Psychiatry, 2014, 85, 2, 130

    CrossRef

  7. 7
    Santiago Perez-Lloret, María Verónica Rey, Anne Pavy-Le Traon, Olivier Rascol, Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders, Expert Opinion on Orphan Drugs, 2014, 2, 5, 509

    CrossRef

  8. 8
    Katsuhito Nagai, Hiroki Konishi, Effect of fluoxetine and pergolide on expression of nucleoside transporters and nucleic-related enzymes in mouse brain, Fundamental & Clinical Pharmacology, 2014, 28, 2
  9. 9
    Marina Picillo, Roberto Erro, Marianna Amboni, Katia Longo, Carmine Vitale, Marcello Moccia, Angela Pierro, Sara Scannapieco, Gabriella Santangelo, Emanuele Spina, Giuseppe Orefice, Paolo Barone, Maria Teresa Pellecchia, Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients, Parkinsonism & Related Disorders, 2014,

    CrossRef

  10. 10
    Gordon W. Duncan, Tien K. Khoo, Alison J. Yarnall, John T. O'Brien, Shirley Y. Coleman, David J. Brooks, Roger A. Barker, David J. Burn, Health-related quality of life in early Parkinson's disease: The impact of nonmotor symptoms, Movement Disorders, 2014, 29, 2
  11. 11
    B.B. Averbeck, S.S. O'Sullivan, A. Djamshidian, Impulsive and Compulsive Behaviors in Parkinson's Disease, Annual Review of Clinical Psychology, 2014, 10, 1, 553

    CrossRef

  12. 12
    Elke Kalbe, Annette Petrelli, Leichte kognitive Störungen und Demenz bei Patienten mit Morbus Parkinson, Zeitschrift für Neuropsychologie, 2014, 25, 1, 17

    CrossRef

  13. 13
    Regina Katzenschlager, Parkinson’s disease: recent advances, Journal of Neurology, 2014, 261, 5, 1031

    CrossRef

  14. 14
    Linn Katus, Alexander Shtilbans, Perioperative Management of Patients with Parkinson's Disease, The American Journal of Medicine, 2014, 127, 4, 275

    CrossRef

  15. 15
    Susan H Fox, Pimavanserin as treatment for Parkinson's disease psychosis, The Lancet, 2014, 383, 9916, 494

    CrossRef

  16. 16
    Klemencja Berghauzen-Maciejewska, Katarzyna Kuter, Wacław Kolasiewicz, Urszula Głowacka, Anna Dziubina, Krystyna Ossowska, Jadwiga Wardas, Pramipexole but not imipramine or fluoxetine reverses the “depressive-like” behaviour in a rat model of preclinical stages of Parkinson's disease, Behavioural Brain Research, 2014, 271, 343

    CrossRef

  17. 17
    Dag Aarsland, John-Paul Taylor, Daniel Weintraub, Psychiatric issues in cognitive impairment, Movement Disorders, 2014, 29, 5
  18. 18
    Brian P. Gomoll, Brandon D. Sanders, Maria T. Caserta, Psychopharmacologic Treatments for Alzheimer Disease and Related Dementias, Psychopharm Review, 2014, 49, 1, 9

    CrossRef

  19. 19
    S. Baillon, M. Dennis, N. Lo, J. Lindesay, Screening for depression in Parkinson's disease: the performance of two screening questions, Age and Ageing, 2014, 43, 2, 200

    CrossRef

  20. 20
    Mauro Pettorruso, Luisa De Risio, Giovanni Martinotti, Marco Di Nicola, Filippo Ruggeri, Gianluigi Conte, Massimo Di Giannantonio, Luigi Janiri, Targeting the Glutamatergic System to Treat Pathological Gambling: Current Evidence and Future Perspectives, BioMed Research International, 2014, 2014, 1

    CrossRef

  21. 21
    Fabrizio Stocchi, Paola Stirpe, The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms, Journal of Neural Transmission, 2014,

    CrossRef

  22. 22
    Jennifer G. Goldman, Caroline Williams-Gray, Roger A. Barker, John E. Duda, James E. Galvin, The spectrum of cognitive impairment in Lewy body diseases, Movement Disorders, 2014, 29, 5
  23. 23
    Connie Marras, Alexander I. Tröster, Jaime Kulisevsky, Glenn T. Stebbins, The tools of the trade: A state of the art “How to Assess Cognition” in the patient with Parkinson's disease, Movement Disorders, 2014, 29, 5
  24. 24
    Sarah Baillon, James Lindesay, Pravin Prabhakaran, Oli Hands, Jonathan Murray, Suzanne Stacey, Sandhya Gaur, Aniruddha Rajkonwar, Jayaraj Padmanabhan, Deepak Shukla, Santanu Chakrabarti, Nelson Lo, Michael Dennis, The utility of the Edinburgh Depression Scale as a screening tool for depression in Parkinson's disease, International Journal of Geriatric Psychiatry, 2014, 29, 7
  25. 25
    Lisa Klingelhoefer, Elisaveta Sokolov, K. Ray Chaudhuri, Therapeutic options for nocturnal problems in Parkinson’s disease and atypical parkinsonian disorders, Journal of Neural Transmission, 2014,

    CrossRef

  26. 26
    Juan C. Giugni, Michael S. Okun, Treatment of advanced Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 450

    CrossRef

  27. 27
    Barbara Connolly, Susan H. Fox, Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease, Neurotherapeutics, 2014, 11, 1, 78

    CrossRef

  28. 28
    Jennifer G. Goldman, Samantha Holden, Treatment of Psychosis and Dementia in Parkinson’s Disease, Current Treatment Options in Neurology, 2014, 16, 3

    CrossRef

  29. 29
    Lynn Marie Trotti, Donald L. Bliwise, Treatment of the Sleep Disorders Associated with Parkinson’s Disease, Neurotherapeutics, 2014, 11, 1, 68

    CrossRef

  30. 30
    Jori Fleisher, Nabila Dahodwala, Best Practices in Neurological Care, 2014,

    CrossRef

  31. 31
    Vanja C. Douglas, S. Andrew Josephson, Aminoff's Neurology and General Medicine, 2014,

    CrossRef

  32. 32
    Tiago A Mestre, Mateusz Zurowski, Susan H Fox, 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders, Expert Opinion on Investigational Drugs, 2013, 22, 4, 411

    CrossRef

  33. 33
    Laura B. Zahodne, Michael Marsiske, Dawn Bowers, A latent class analysis of psychological disturbance in Parkinson's disease, International Journal of Geriatric Psychiatry, 2013, 28, 10
  34. 34
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Advanced Parkinson's disease: Clinical characteristics and treatment. Part II, Neurología (English Edition), 2013, 28, 9, 558

    CrossRef

  35. 35
    Lars Brichta, Paul Greengard, Marc Flajolet, Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems, Trends in Neurosciences, 2013, 36, 9, 543

    CrossRef

  36. 36
    Bessy Thrash-Williams, Manuj Ahuja, Senthilkumar S. Karuppagounder, Subramaniam Uthayathas, Vishnu Suppiramaniam, Muralikrishnan Dhanasekaran, Assessment of Therapeutic Potential of Amantadine in Methamphetamine Induced Neurotoxicity, Neurochemical Research, 2013, 38, 10, 2084

    CrossRef

  37. 37
    Eric Wexler, Clinical Neurogenetics, Neurologic Clinics, 2013, 31, 4, 1121

    CrossRef

  38. 38
    Laura Marsh, Depression and Parkinson’s Disease: Current Knowledge, Current Neurology and Neuroscience Reports, 2013, 13, 12

    CrossRef

  39. 39
    Krystyna Ossowska, Elżbieta Lorenc-Koci, Depression in Parkinson's disease, Pharmacological Reports, 2013, 65, 6, 1545

    CrossRef

  40. 40
    Jack J. Chen, Laura Marsh, Depression in Parkinson's Disease: Identification and Management, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013, 33, 9
  41. 41
    Julian Hellmann-Regen, Dominique Piber, Kim Hinkelmann, Stefan M. Gold, Christoph Heesen, Carsten Spitzer, Matthias Endres, Christian Otte, Depressive syndromes in neurological disorders, European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, S2, 123

    CrossRef

  42. 42
    Angelo Antonini, Daniela Calandrella, Marcelo Merello, Konstantinos Koutsikos, Manuela Pilleri, Effects of rotigotine on Parkinson's disease-related sleep disturbances, Expert Opinion on Pharmacotherapy, 2013, 14, 18, 2571

    CrossRef

  43. 43
    Theresa A Zesiewicz, Pablo Martinez-Martin, Effects of rotigotine transdermal system on non-motor symptoms in Parkinson’s disease: an overview, Expert Review of Neurotherapeutics, 2013, 13, 12, 1329

    CrossRef

  44. 44
    Santiago Perez-Lloret, María Verónica Rey, Anne Pavy-Le Traon, Olivier Rascol, Emerging drugs for autonomic dysfunction in Parkinson's disease, Expert Opinion on Emerging Drugs, 2013, 18, 1, 39

    CrossRef

  45. 45
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II, Neurología, 2013, 28, 9, 558

    CrossRef

  46. 46
    Yan Wang, Cheng-long Xie, Wen-Wen Wang, Lin Lu, Deng-lei Fu, Xiao-tong Wang, Guo-qing Zheng, Epidemiology of complementary and alternative medicine use in patients with Parkinson’s disease, Journal of Clinical Neuroscience, 2013, 20, 8, 1062

    CrossRef

  47. 47
    P. F. Worth, How to treat Parkinson's disease in 2013, Clinical Medicine, 2013, 13, 1, 93

    CrossRef

  48. 48
    Scott Kaplan, Daniel Tarsy, Initial Treatment of Parkinson’s Disease: An Update, Current Treatment Options in Neurology, 2013, 15, 4, 377

    CrossRef

  49. 49
    Manuela Pilleri, Konstantinos Koutsikos, Angelo Antonini, Is there room for new non-dopaminergic treatments in Parkinson’s disease?, Journal of Neural Transmission, 2013, 120, 2, 349

    CrossRef

  50. 50
    Kalf JG, Management of dysphagia and drooling in patients with Parkinson’s disease, Neurodegenerative Disease Management, 2013, 3, 1, 71

    CrossRef

  51. 51
    Fabienne Sprenger, Werner Poewe, Management of Motor and Non-Motor Symptoms in Parkinson’s Disease, CNS Drugs, 2013, 27, 4, 259

    CrossRef

  52. 52
    Christoph Schroeder, Jens Jordan, Horacio Kaufmann, Management of Neurogenic Orthostatic Hypotension in Patients with Autonomic Failure, Drugs, 2013, 73, 12, 1267

    CrossRef

  53. 53
    Nathan Herrmann, Connie Marras, Hadas D. Fischer, Xuesong Wang, Geoff M. Anderson, Paula A. Rochon, Management of Neuropsychiatric Symptoms in Long-Term Care Residents with Parkinson’s Disease, Drugs & Aging, 2013, 30, 1, 19

    CrossRef

  54. 54
    David Devos, Caroline Moreau, Arnaud Delval, Kathy Dujardin, Luc Defebvre, Regis Bordet, Methylphenidate, CNS Drugs, 2013, 27, 1, 1

    CrossRef

  55. 55
    Barbara A. Pickut, Wim Van Hecke, Eric Kerckhofs, Peter Mariën, Sven Vanneste, Patrick Cras, Paul M. Parizel, Mindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI, Clinical Neurology and Neurosurgery, 2013, 115, 12, 2419

    CrossRef

  56. 56
    Kenji Tagai, Tomoyuki Nagata, Shunichiro Shinagawa, Norifumi Tsuno, Motohiro Ozone, Kazuhiko Nakayama, Mirtazapine improves visual hallucinations in Parkinson's disease: a case report, Psychogeriatrics, 2013, 13, 2
  57. 57
    Poul Jennum, Geert Mayer, Yo-El Ju, Ron Postuma, Morbidities in rapid eye movement sleep behavior disorder, Sleep Medicine, 2013, 14, 8, 782

    CrossRef

  58. 58
    Daniel Weintraub, Neuropsychiatric Symptoms in Parkinson Disease and Dementia with Lewy Bodies: What Geriatric Psychiatry Can Learn, The American Journal of Geriatric Psychiatry, 2013, 21, 6, 497

    CrossRef

  59. 59
    David Devos, Caroline Moreau, Kathy Dujardin, Ioav Cabantchik, Luc Defebvre, Regis Bordet, New Pharmacological Options for Treating Advanced Parkinson’s Disease, Clinical Therapeutics, 2013, 35, 10, 1640

    CrossRef

  60. 60
    Nico J. Weerkamp, Gerrit Tissingh, Petra J.E. Poels, Systse U. Zuidema, Marten Munneke, Raymond T.C.M. Koopmans, Bastiaan R. Bloem, Nonmotor Symptoms in Nursing Home Residents with Parkinson's Disease: Prevalence and Effect on Quality of Life, Journal of the American Geriatrics Society, 2013, 61, 10
  61. 61
    Victor W. Sung, Anthony P. Nicholas, Nonmotor Symptoms in Parkinson's Disease, Neurologic Clinics, 2013, 31, 3, S1

    CrossRef

  62. 62
    Anna Hussl, Klaus Seppi, Werner Poewe, Nonmotor symptoms in Parkinson’s disease, Expert Review of Neurotherapeutics, 2013, 13, 6, 581

    CrossRef

  63. 63
    Lorraine V. Kalia, Jonathan M. Brotchie, Susan H. Fox, Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials, Movement Disorders, 2013, 28, 2
  64. 64
    Santiago Perez-Lloret, María Verónica Rey, Anne Pavy-Le Traon, Olivier Rascol, Orthostatic hypotension in Parkinson’s disease, Neurodegenerative Disease Management, 2013, 3, 4, 363

    CrossRef

  65. 65
    David J. Irwin, Virginia M.-Y. Lee, John Q. Trojanowski, Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies, Nature Reviews Neuroscience, 2013, 14, 9, 626

    CrossRef

  66. 66
    Tom Foltynie, Joshua Kahan, Parkinson’s disease: an update on pathogenesis and treatment, Journal of Neurology, 2013, 260, 5, 1433

    CrossRef

  67. 67
    Gabriella Santangelo, Paolo Barone, Luigi Trojano, Carmine Vitale, Pathological gambling in Parkinson's disease. A comprehensive review, Parkinsonism & Related Disorders, 2013, 19, 7, 645

    CrossRef

  68. 68
    Walter Maetzler, Josefa Domingos, Karin Srulijes, Joaquim J. Ferreira, Bastiaan R. Bloem, Quantitative wearable sensors for objective assessment of Parkinson's disease, Movement Disorders, 2013, 28, 12
  69. 69
    Michele Tinazzi, Giovanni Abbruzzese, Angelo Antonini, Roberto Ceravolo, Giovanni Fabbrini, Patrizia Lessi, Paolo Barone, Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study, Parkinsonism & Related Disorders, 2013, 19, 12, 1130

    CrossRef

  70. 70
    Kangdi Zhu, Jacobus J. Hilten, Hein Putter, Johan Marinus, Risk factors for hallucinations in Parkinson's disease: Results from a large prospective cohort study, Movement Disorders, 2013, 28, 6
  71. 71
    K. Ray Chaudhuri, Pablo Martinez-Martin, Angelo Antonini, Richard G. Brown, Joseph H. Friedman, Marco Onofrj, Erwin Surmann, Liesbet Ghys, Claudia Trenkwalder, Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER, Parkinsonism & Related Disorders, 2013, 19, 7, 660

    CrossRef

  72. 72
    Amanda Lakraj, Narges Moghimi, Bahman Jabbari, Sialorrhea: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum Toxins, Toxins, 2013, 5, 5, 1010

    CrossRef

  73. 73
    Philippe Huot, Susan H. Fox, The serotonergic system in motor and non-motor manifestations of Parkinson’s disease, Experimental Brain Research, 2013, 230, 4, 463

    CrossRef

  74. 74
    Brendon P. Boot, Eric M. McDade, Scott M. McGinnis, Bradley F. Boeve, Treatment of Dementia With Lewy Bodies, Current Treatment Options in Neurology, 2013, 15, 6, 738

    CrossRef

  75. 75
    Wolfgang H. Jost, Urological problems in Parkinson’s disease: clinical aspects, Journal of Neural Transmission, 2013, 120, 4, 587

    CrossRef

  76. 76
    Jack Chen, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  77. 77
    Jack J. Chen, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  78. 78
    Mark Stacy, Parkinson’s Disease: Medical and Surgical Treatment, 2013,

    CrossRef

  79. 79
    Yoshikuni Mizuno, An update on the management of juvenile and young-onset Parkinson’s disease, Future Neurology, 2012, 7, 5, 581

    CrossRef

  80. 80
    Kristian Winge, Kurt K. Nielsen, Bladder dysfunction in advanced Parkinson's disease, Neurourology and Urodynamics, 2012, 31, 8
  81. 81
    D. Aarsland, C. Ballard, A. Rongve, M. Broadstock, P. Svenningsson, Clinical Trials of Dementia With Lewy Bodies and Parkinson’s Disease Dementia, Current Neurology and Neuroscience Reports, 2012, 12, 5, 492

    CrossRef

  82. 82
    Per Svenningsson, Eric Westman, Clive Ballard, Dag Aarsland, Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment, The Lancet Neurology, 2012, 11, 8, 697

    CrossRef

  83. 83
    Tohru Kitada, Julianna J. Tomlinson, Hei Sio Ao, David A. Grimes, Michael G. Schlossmacher, Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson Disease, Current Treatment Options in Neurology, 2012, 14, 3, 230

    CrossRef

  84. 84
    D. Piber, K. Hinkelmann, S.M. Gold, C. Heesen, C. Spitzer, M. Endres, C Otte, Depression und neurologische Erkrankungen, Der Nervenarzt, 2012, 83, 11, 1423

    CrossRef

  85. 85
    Barbara S Connolly, Susan H Fox, Drug treatments for the neuropsychiatric complications of Parkinson’s disease, Expert Review of Neurotherapeutics, 2012, 12, 12, 1439

    CrossRef

  86. 86
    Werner Poewe, Philipp Mahlknecht, Joseph Jankovic, Emerging therapies for Parkinsonʼs disease, Current Opinion in Neurology, 2012, 25, 4, 448

    CrossRef

  87. 87
    Naveed M Malek, Donald G Grosset, Enhancing dopamine treatments: worth the effort?, Neurodegenerative Disease Management, 2012, 2, 4, 365

    CrossRef

  88. 88
    Robert F Leeman, Benjamin E Billingsley, Marc N Potenza, Impulse control disorders in Parkinson’s disease: background and update on prevention and management, Neurodegenerative Disease Management, 2012, 2, 4, 389

    CrossRef

  89. 89
    Jennifer Cheng, Hunter Groninger, Modafinil #259, Journal of Palliative Medicine, 2012, 15, 12, 1388

    CrossRef

  90. 90
    Kurt A Jellinger, Neurobiology of cognitive impairment in Parkinson’s disease, Expert Review of Neurotherapeutics, 2012, 12, 12, 1451

    CrossRef

  91. 91
    Michael J. Howell, Parasomnias: An Updated Review, Neurotherapeutics, 2012, 9, 4, 753

    CrossRef

  92. 92
    Santiago Perez-Lloret, Olivier Rascol, Parkinson disease: Serotonin reuptake inhibitors for depression in PD, Nature Reviews Neurology, 2012, 8, 7, 365

    CrossRef

  93. 93
    T. S. Armstrong, M. R. Gilbert, Practical strategies for management of fatigue and sleep disorders in people with brain tumors, Neuro-Oncology, 2012, 14, suppl 4, iv65

    CrossRef

  94. 94
    Sergio E. Starkstein, Simone Brockman, Bradleigh D. Hayhow, Psychiatric syndromes in Parkinsonʼs disease, Current Opinion in Psychiatry, 2012, 25, 6, 468

    CrossRef

  95. 95
    E. Roze, Quelles thérapeutiques proposer dans la maladie de Parkinson du sujet âgé ?, Les cahiers de l'année gérontologique, 2012, 4, 2, 50

    CrossRef

  96. 96
    Steffen Paschen, Günther Deuschl, SSRI und SNRI sind wirksam und sicher, InFo Neurologie & Psychiatrie, 2012, 14, 7-8, 20

    CrossRef

  97. 97
    Joseph Jankovic, Werner Poewe, Therapies in Parkinsonʼs disease, Current Opinion in Neurology, 2012, 25, 4, 433

    CrossRef

  98. 98
    Camille P Vaughan, What is the best approach for treating urinary incontinence in Parkinson’s disease?, Aging Health, 2012, 8, 5, 525

    CrossRef

  99. 99
    Mariah J. Lelos, Eilís Dowd, Stephen B. Dunnett, Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I, 2012,

    CrossRef

  100. 100
    Roy G Elbers, John Verhoef, Erwin EH van Wegen, Henk W Berendse, Gert Kwakkel, Interventions for fatigue in Parkinson's disease, The Cochrane Library,